Price
No data yet.
Social Signal Score
Analyst Ratings
6 analystsRevenue
$9.45M+7981.55%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Thomas J. Errico
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 83
- Beta
- 1.01
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -13.74
Financials
Revenue
$9.45M+7981.6%Net Income
$-3.06MEBITDA
$-2.74MFree Cash Flow
$-3.52MEPS (diluted)
$-0.33Shares Outstanding (diluted)
9.40M-15.4%Operating Expenses
$10.95MCash & Debt
$10.04MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $32.03M | $-13.97M | $-1.65 |
| 2024 | $25.18M | $-11.89M | $-1.59 |
| 2023 | $16.03M | $-18.83M | $-3.42 |
| 2022 | $8.59M | $-22.16M | $-4.69 |
| 2021 | $5.45M | $-17.22M | $-4.36 |
| 2020 | $3.50M | $-23.51M | $-9.04 |
| 2019 | $2.39M | $-45.15M | $-23.05 |
| 2018 | $993.0K | $-55.82M | $-28.61 |
| 2017 | $811.5K | $-35.79M | $-5.52 |
| 2016 | $254.1K | $-15.74M | $-1.57 |
Valuation
ECORhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80-20.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·5h ago·Negative
electroCore to Present at Planet MicroCap Toronto 2026 powered by MicroCapClub ROCKAWAY, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will be presenting at Planet MicroCap Toronto 2026 Powered by MicroCapClub being held at the Arcadian Court & Loft.
View source ↗ - Newsseekingalpha.com·25d ago·Neutral
electroCore Has A Line Of Sight At Cash Breakeven electroCore is showing operational and financial improvement, driven by sales force expansion and strong Quell Fibromyalgia growth. ECOR targets >30% FY26 revenue growth, 85%+ gross margins, and positive adjusted EBITDA by Q3/27 without further dilution. Key catalysts include FDA submissions for CIPN, PTSD label expansion, and broadening TAC-STIM sales to first responders and intelligence agencies.
View source ↗ - Newszacks.com·33d ago·Neutral
electroCore (ECOR) Stock Jumps 6.9%: Will It Continue to Soar? electroCore (ECOR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
View source ↗
Earnings
Wed, Nov 4(in 13 days)
Consensus estimate $-0.26 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.33 vs $-0.42beat
- Wed, May 6$-0.59 vs $-0.59beat
- Thu, Mar 19$-0.34 vs $-0.35beat
- Wed, Nov 5$-0.40 vs $-0.36miss
- Wed, Aug 6$-0.35 vs $-0.32miss
- Wed, May 7$-0.47 vs $-0.56beat
Estimates and results for ECOR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ECOR officers and directors.
- Bought
- $3.5m
- Sold
- $946k
23 trades
9 trades
- Errico Thomas J.bought
- Fox Michaelbought
- Lev Joshua S.sold
- Lev Joshua S.sold
- Lev Joshua S.sold
- Errico Thomas J.bought
- Lev Joshua S.sold
- Lev Joshua S.sold
68 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ECOR.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.